HomeABCL • NASDAQ
AbCellera Biologics Inc
$3.31
Ene 27, 3:36:06 PM GMT-5 · USD · NASDAQ · Disclaimer
StockSegurong nakalista sa USMay headquarter sa CA
Nakaraang pagsara
$3.48
Sakop ng araw
$3.27 - $3.46
Sakop ng taon
$2.34 - $5.62
Market cap
977.66M USD
Average na Volume
3.45M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(USD)Set 2024Y/Y na pagbabago
Kita
6.51M-1.39%
Gastos sa pagpapatakbo
59.20M151.15%
Net na kita
-51.11M-78.63%
Net profit margin
-785.42-81.16%
Kita sa bawat share
-0.17-70.00%
EBITDA
-56.74M-15.44%
Aktuwal na % ng binabayarang buwis
18.40%
Kabuuang asset
Kabuuang sagutin
(USD)Set 2024Y/Y na pagbabago
Cash at mga panandaliang investment
643.14M-18.16%
Kabuuang asset
1.39B-7.89%
Kabuuang sagutin
314.73M-4.46%
Kabuuang equity
1.08B
Natitirang share
295.37M
Presyo para makapag-book
0.95
Return on assets
-16.69%
Return on capital
-20.08%
Net change in cash
(USD)Set 2024Y/Y na pagbabago
Net na kita
-51.11M-78.63%
Cash mula sa mga operasyon
-28.88M-27,147.17%
Cash mula sa pag-invest
3.70M128.92%
Cash mula sa financing
3.14M-52.56%
Net change in cash
-21.67M-195.86%
Malayang cash flow
-10.48M72.64%
Tungkol
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
Itinatag
2012
Mga Empleyado
586
Search
I-clear ang paghahanap
Isara ang paghahanap
Mga app ng Google
Pangunahing menu